Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896526 | 1.00 | RIPK2 (0.34) | RIPK2CRHR1SCN9APOLBSMO | |
| SCHEMBL9898624 | 1.00 | RIPK2 (0.34) | RIPK2CRHR1SCN9APOLBSMO | |
| SCHEMBL9895883 | 0.94 | RIPK2 (0.34) | RIPK2CRHR1SCN9APOLBAR | |
| SCHEMBL9895885 | 0.94 | RIPK2 (0.34) | RIPK2CRHR1SCN9APOLBAR | |
| SCHEMBL9896505 | 0.94 | RIPK2 (0.34) | RIPK2CRHR1SCN9APOLBAR | |
| SCHEMBL9896432 | 0.93 | RIPK2 (0.35) | RIPK2CRHR1SCN9APOLBAR | |
| SCHEMBL9896953 | 0.93 | RIPK2 (0.35) | RIPK2CRHR1SCN9APOLBAR | |
| SCHEMBL9896430 | 0.93 | RIPK2 (0.35) | RIPK2CRHR1SCN9APOLBAR | |
| SCHEMBL9896920 | 0.92 | SMO (0.35) | RIPK2CRHR1SCN9APOLBSMO | |
| SCHEMBL9896916 | 0.92 | SMO (0.35) | RIPK2CRHR1SCN9APOLBSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | claimed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | claimed |
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | RIPK2 3633/4885CRHR1 3405/4885SCN9A 2014/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | RIPK2 2831/4885CRHR1 3977/4885SCN9A 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.